Xeris Biopharma Holdings, Inc. - Common Stock (XERS)

Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio. On the company’s earnings call, Chief Executive Officer John Shan

Xeris (XERS) Q1 2026 Earnings Call Transcript

Xeris Biopharma (XERS) Q4 2025 Earnings Transcript

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.

Let's have a look at the gap up and gap down stocks in today's session.

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to $280–$290M.

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS).

The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies.

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.